June 21, 2018
trial_results

Pediatric Oncology – Key Results from ASCO 2018

Pembrolizumab demonstrated durable anti-tumor activity in various tumors specially Hodgkin Lymphoma (ORR: 50%, mPFS: 12.2 months, 12 month PFS rate: 59.7%). The results indicate further study of pembrolizumab in pediatric patients with particulate interest in Lymphoma Phase 2 Study results confirms PR rate of 72% with that of phase 1 […]
May 14, 2018
biosimilar caption

Biosimilar Clinical Development – A Strategic Lever?

The presentation gives some key insights on the emerging biosimilars developer landscape with focus on US, EU, China, Japan, South Korea, MENA and Indian markets. Furthermore, it provides a detailed analysis on Clinical differentiation of players for major products (Bevacizumab, Trastuzumab, Adalimumab, Rituximab, Infliximab and etanercept).
July 17, 2017
clinical_dev_biosimilar

Ongoing Biosimilar Clinical Development in Oncology

As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute […]